Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Enterprise Value (2017 - 2025)

Historic Enterprise Value for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to -$1.1 billion.

  • Crinetics Pharmaceuticals' Enterprise Value fell 2661.78% to -$1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 billion, marking a year-over-year decrease of 2661.78%. This contributed to the annual value of -$1.4 billion for FY2024, which is 14186.07% down from last year.
  • Crinetics Pharmaceuticals' Enterprise Value amounted to -$1.1 billion in Q3 2025, which was down 2661.78% from -$2.3 billion recorded in Q2 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Enterprise Value peaked at -$150.7 million during Q1 2021, and registered a low of -$2.5 billion during Q1 2025.
  • Moreover, its 5-year median value for Enterprise Value was -$408.5 million (2022), whereas its average is -$730.8 million.
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Enterprise Value skyrocketed by 3524.48% in 2023, and later plummeted by 22622.25% in 2024.
  • Quarter analysis of 5 years shows Crinetics Pharmaceuticals' Enterprise Value stood at -$334.2 million in 2021, then decreased by 0.45% to -$335.7 million in 2022, then crashed by 66.76% to -$559.9 million in 2023, then plummeted by 141.86% to -$1.4 billion in 2024, then rose by 19.33% to -$1.1 billion in 2025.
  • Its Enterprise Value was -$1.1 billion in Q3 2025, compared to -$2.3 billion in Q2 2025 and -$2.5 billion in Q1 2025.